T-Cell Immunotherapy for Cancer - Pipeline Analysis

Published: Aug, 2016 | Pages: 75 | Publisher: RNCOS
Industry: Healthcare | Report Format: Electronic (PDF)

Cancer is a leading cause of death worldwide. According to GLOBOCAN 2012, the incidence of cancer is expected to increase from 14 Million in 2012 to approximately 21 Million by 2030. Although conventional therapies, such as chemotherapy and radiotherapy, have been the roots to slow down the progression of tumors, however till date no complete treatment of this disease is available in the market. Furthermore, these conventional therapies have numerous side-effects associated with them, such as nausea, hair loss and abnormal blood cell counts. These limitations and adverse effects of conventional therapies have therefore created a significant need for the treatment of cancer. This led to development of new therapies to curb the prevalence of this disease with minimal side-effects. One such therapy is cancer immunotherapy, particularly T-cell immunotherapy. T-cell immunotherapy has shown great promise in the treatment of patients with late-stage cancer.

According to RNCOS' new research report "T-Cell Immunotherapy for Cancer - Pipeline Analysis", T-cell immunotherapy is one of the most widely researched fields in the recent years. The high potential of T-cell based therapies to cure various types of cancer indications makes it a popular research area. Numerous researches are being performed across the globe to explore the potential of T-cell immunotherapy for the treatment of different therapeutic areas. The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some critical issues. T-cell immunotherapy has emerged as one of the innovative and potent arm of the Immunotherapeutics market.

The report provides an in-depth study on the current state of the T-Cell Immunotherapy industry. Currently, there is no commercialized T-cell immunotherapy; however due to high venture capitalist investments and increasing research related activities, this market is slated to witness a precipitous growth in the coming years. The report provides detailed analysis of various other factors affecting the growth of the market.

The report also covers the global as well as regional prevalence of major types of cancer for which T-cell immunotherapy is used. These cancers include leukemia, lymphoma, melanoma, ovarian cancer, and bladder cancer amongst others. This will help the companies to gain knowledge regarding the target population for various immunotherapies globally, and at regional level.

The report also provides detailed pipeline analysis of T-cell immunotherapy. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the T-cell immunotherapy market, such as phases, geographies, vectors used, therapeutic indications, technology types, and key players. The segment also covers the list of the key ongoing clinical trials along with their clinical phases. According to the research, CAR-T is the most widely used technology by the companies. Moreover, the report also suggests that most of the T-cell immunotherapies are in the research or pre-clinical phase. Limited number of therapies has been able to cross Phase I of the clinical trials.

Several companies and academic institutions are operating in this market with a focus on developing T-cell immunotherapy for 'difficult to treat' cancers. These companies are also receiving various funding, grants, and investment from non-industry participants, and other companies and venture capitalist firms, which are aiding them to develop new products. The report provides details about major venture capitalist investments, government grants, and IPO raised in this market.

Finally, with a view to understanding the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global T-cell Immunotherapy market. The profiles of these companies include business overview, financials, product pipeline, and their strength and weakness analysis. Major players operating in the T-cell Immunotherapy market are Adaptimmune Therapeutics plc, Juno Therapeutics, Inc., Kite Pharma, Inc., Novartis International AG, Tessa Therapeutics Pte Ltd., Gradalis, Inc., Immunovative Therapies, Ltd., Lion Biotechnologies, Inc., Atara Biotherapeutics, Inc., Celgene Corporation, Cellular Biomedicine Group, GlaxoSmithKline plc, Immunocore Ltd., Cell Medica, and Inovio Pharmaceuticals, Inc.

Table of Contents
1. Analyst View
2. Research Methodology
3. Introduction
4. Market Dynamics
4.1 Market Drivers
4.1.1 Increasing Number of Investments and Grants
4.1.2 Technological Advancements
4.1.3 Robust and Opportunistic Pipeline
4.1.4 Collaboration Amongst Industry Players and Non-Industry Participants
4.1.5 Rising Research Related Activities
4.1.6 Venture Capitalist Funding
4.2 Challenges
4.2.1 Manufacturing and Regulatory Challenges
4.2.2 High Cost of Manufacturing Coupled With Demand for Scalability
4.2.3 Limited Validation of CAR-T Therapy Outside Of CD19+ Hematological Malignancies
4.3 Opportunities
4.3.1 Juno Therapeutics, Kite Pharma, Novartis Offering Great Opportunities
4.3.2 CAR-T Therapies Are Likely To Gain Momentum in Near Future
5. Major Therapeutic Areas for T-Cell Therapies
5.1 Hematological Malignancies
5.1.1 Leukemia
5.1.2 Lymphoma
5.1.3 Multiple Myeloma
5.2 Solid Tumours
5.2.1 Melanoma
5.2.2 Bladder Cancer
5.2.3 Kidney Cancer
5.2.4 Ovarian Cancer
5.2.5 Breast Cancer
5.2.6 Lung Cancer
6. Pipeline Analysis
7. Investments in T-Cell Immunotherapy
8. Key Player Analysis
8.1 Adaptimmune Therapeutics plc
8.2 Juno Therapeutics, Inc.
8.3 Kite Pharma, Inc.
8.4 Novartis International AG
8.5 Tessa Therapeutics Pte Ltd.
8.6 Gradalis, Inc.
8.7 Immunovative Therapies, Ltd.
8.8 Lion Biotechnologies, Inc.
8.9 Atara Biotherapeutics, Inc.
8.10 Celgene Corporation
8.11 Cellular Biomedicine Group
8.12 GlaxoSmithKline plc.
8.13 Immunocore Ltd.
8.14 Cell Medica
8.15 Inovio Pharmaceuticals, Inc.

List of Tables:

Table 4-1: Global - Major Investments & Grants in T-Cell Immunotherapy (Million US$)
Table 5-1: Global - Cancer Prevalence (Million), 2015 & 2025
Table 5-2: Global - Leukemia Prevalence ('000), 2015 & 2025 
Table 5-3: North America - Leukemia Prevalence ('000), 2015 & 2025
Table 5-4: Europe - Leukemia Prevalence ('000), 2015 & 2025
Table 5-5: Asia-Pacific - Leukemia Prevalence ('000), 2015 & 2025
Table 5-6: Rest of the World - Leukemia Prevalence ('000), 2015 & 2025
Table 5-7: Global - Lymphoma Prevalence ('000), 2015 & 2025
Table 5-8: North America - Lymphoma Prevalence ('000), 2015 & 2025
Table 5-9: Europe - Lymphoma Prevalence ('000), 2015 & 2025
Table 5-10: Asia-Pacific - Lymphoma Prevalence ('000), 2015 & 2025
Table 5-11: Rest of the World - Lymphoma Prevalence ('000), 2015 & 2025
Table 5-12: Global - Multiple Myeloma Prevalence ('000), 2015 & 2025
Table 5-13: North America - Multiple Myeloma Prevalence ('000), 2015 & 2025
Table 5-14: Europe - Multiple Myeloma Prevalence ('000), 2015 & 2025
Table 5-15: Asia-Pacific - Multiple Myeloma Prevalence ('000), 2015 & 2025
Table 5-16: Rest of the World - Multiple Myeloma Prevalence ('000), 2015 & 2025
Table 5-17: Global - Melanoma Prevalence ('000), 2015 & 2025
Table 5-18: North America - Melanoma Prevalence ('000), 2015 & 2025
Table 5-19: Europe - Melanoma Prevalence ('000), 2015 & 2025
Table 5-20: Asia-Pacific - Melanoma Prevalence ('000), 2015 & 2025
Table 5-21: Rest of the World - Melanoma Prevalence ('000), 2015 & 2025
Table 5-22: Global - Bladder Cancer Prevalence ('000), 2015 & 2025
Table 5-23: North America - Bladder Cancer Prevalence ('000), 2015 & 2025
Table 5-24: Europe - Bladder Cancer Prevalence ('000), 2015 & 2025
Table 5-25: Asia-Pacific - Bladder Cancer Prevalence ('000), 2015 & 2025
Table 5-26: Rest of the World - Bladder Cancer Prevalence ('000), 2015 & 2025
Table 5-27: Global - Kidney Cancer Prevalence ('000), 2015 & 2025
Table 5-28: North America - Kidney Cancer Prevalence ('000), 2015 & 2025
Table 5-29: Europe - Kidney Cancer Prevalence ('000), 2015 & 2025
Table 5-30: Asia-Pacific - Kidney Cancer Prevalence ('000), 2015 & 2025
Table 5-31: Rest of the World - Kidney Cancer Prevalence ('000), 2015 & 2025
Table 5-32: Global - Ovarian Cancer Prevalence ('000), 2015 & 2025
Table 5-33: North America - Ovarian Cancer Prevalence ('000), 2015 & 2025
Table 5-34: Europe - Ovarian Cancer Prevalence ('000), 2015 & 2025
Table 5-35: Asia-Pacific - Ovarian Cancer Prevalence ('000), 2015 & 2025
Table 5-36: Rest of the World - Ovarian Cancer Prevalence ('000), 2015 & 2025
Table 5-37: Global - Breast Cancer Prevalence ('000), 2015 & 2025
Table 5-38: North America - Breast Cancer Prevalence ('000), 2015 & 2025
Table 5-39: Europe - Breast Cancer Prevalence ('000), 2015 & 2025
Table 5-40: Asia-Pacific - Breast Cancer Prevalence ('000), 2015 & 2025
Table 5-41: Rest of the World - Breast Cancer Prevalence ('000), 2015 & 2025
Table 5-42: Global - Lung Cancer Prevalence ('000), 2015 & 2025
Table 5-43: North America - Lung Cancer Prevalence ('000), 2015 & 2025
Table 5-44: Europe - Lung Cancer Prevalence ('000), 2015 & 2025
Table 5-45: Asia-Pacific - Lung Cancer Prevalence ('000), 2015 & 2025
Table 5-46: Rest of the World - Lung Cancer Prevalence ('000), 2015 & 2025
Table 6-1: Global T-Cell Immunotherapy Pipeline
Table 7-1: Global - Major Venture Capitalist Investment in T-Cell Immunotherapy
Table 7-2: Global - Major IPO Raised in T-Cell Immunotherapy (Million US$), 2014-2016
Table 8-1: Adaptimmune Therapeutics plc - Total Revenue (Million US$), FY 2014 & FY 2015
Table 8-2: Adaptimmune Therapeutics plc - T-Cell Immunotherapy Pipeline
Table 8-3: Juno Therapeutics, Inc. - Total Revenue (Million US$), 2015
Table 8-4: Juno Therapeutics, Inc. - T-Cell Immunotherapy Pipeline
Table 8-5: Kite Pharma, Inc. - Total Revenue (Million US$), 2015
Table 8-6: Kite Pharma, Inc. - T-Cell Immunotherapy Pipeline
Table 8-7: Novartis - Net Sales (Million US$), 2013, 2014 & 2015
Table 8-8: Novartis - T-Cell Immunotherapy Pipeline
Table 8-9: Tessa Therapeutics Pte Ltd. - T-Cell Immunotherapy Pipeline
Table 8-10: Gradalis, Inc. - T-Cell Immunotherapy Pipeline
Table 8-11: Immunovative Therapies, Ltd. - T-Cell Immunotherapy Pipeline
Table 8-12: Lion Biotechnologies, Inc. - T-Cell Immunotherapy Pipeline
Table 8-13: Atara Biotherapeutics, Inc. - T-Cell Immunotherapy Pipeline 
Table 8-14: Celgene Corporation - Total Revenue (Million US$), 2013, 2014 & 2015
Table 8-15: Celgene Corporation - T-Cell Immunotherapy Pipeline
Table 8-16: Cellular Biomedicine Group - Total Revenue (Million US), 2013, 2014 & 2015
Table 8-17: Cellular Biomedicine Group - T-Cell Immunotherapy Pipeline
Table 8-18: GlaxoSmithKline plc. - Group Turnover (Million US$), 2013, 2014 & 2015
Table 8-19: GlaxoSmithKline plc. - T-Cell Immunotherapy Pipeline
Table 8-20: Immunocore Ltd. - T-Cell Immunotherapy Pipeline
Table 8-21: Cell Medica - T-Cell Immunotherapy Pipeline
Table 8-22: Inovio Pharmaceuticals, Inc. - Revenue (Million US$), 2013, 2014 & 2015
Table 8-23: Inovio Pharmaceuticals, Inc. - T-Cell Immunotherapy Pipeline